PL2143792T3 - Jednołańcuchowe koliste RNA i sposób jego wytwarzania - Google Patents

Jednołańcuchowe koliste RNA i sposób jego wytwarzania

Info

Publication number
PL2143792T3
PL2143792T3 PL08764303T PL08764303T PL2143792T3 PL 2143792 T3 PL2143792 T3 PL 2143792T3 PL 08764303 T PL08764303 T PL 08764303T PL 08764303 T PL08764303 T PL 08764303T PL 2143792 T3 PL2143792 T3 PL 2143792T3
Authority
PL
Poland
Prior art keywords
production
stranded cyclic
cyclic rna
rna
stranded
Prior art date
Application number
PL08764303T
Other languages
English (en)
Inventor
Hiroshi Abe
Yoshihiro Ito
Naoko Abe
Hidekazu Toyobuku
Original Assignee
Riken
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, Otsuka Pharma Co Ltd filed Critical Riken
Publication of PL2143792T3 publication Critical patent/PL2143792T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL08764303T 2007-05-09 2008-05-09 Jednołańcuchowe koliste RNA i sposób jego wytwarzania PL2143792T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007125045A JP5296328B2 (ja) 2007-05-09 2007-05-09 １本鎖環状ｒｎａおよびその製造方法
PCT/JP2008/058990 WO2008140126A1 (ja) 2007-05-09 2008-05-09 １本鎖環状ｒｎａおよびその製造方法
EP08764303.7A EP2143792B1 (en) 2007-05-09 2008-05-09 Single-stranded cyclic RNA, and method of production thereof

Publications (1)

Publication Number Publication Date
PL2143792T3 true PL2143792T3 (pl) 2014-07-31

Family

ID=40002313

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08764303T PL2143792T3 (pl) 2007-05-09 2008-05-09 Jednołańcuchowe koliste RNA i sposób jego wytwarzania

Country Status (25)

Country Link
US (3) US20100137407A1 (pl)
EP (1) EP2143792B1 (pl)
JP (1) JP5296328B2 (pl)
KR (1) KR101525633B1 (pl)
CN (1) CN101679962A (pl)
AR (1) AR072034A1 (pl)
AU (1) AU2008250075B2 (pl)
BR (1) BRPI0811440A2 (pl)
CA (1) CA2685994A1 (pl)
CO (1) CO6241167A2 (pl)
CY (1) CY1115283T1 (pl)
DK (1) DK2143792T3 (pl)
ES (1) ES2446040T3 (pl)
HR (1) HRP20140170T1 (pl)
IL (1) IL201975A (pl)
MX (1) MX2009011101A (pl)
MY (1) MY154495A (pl)
NZ (1) NZ581251A (pl)
PL (1) PL2143792T3 (pl)
PT (1) PT2143792E (pl)
RU (1) RU2523596C2 (pl)
SI (1) SI2143792T1 (pl)
TW (1) TWI468515B (pl)
UA (1) UA101806C2 (pl)
WO (1) WO2008140126A1 (pl)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256191A4 (en) * 2008-02-15 2011-07-06 Riken CYCLIC SINGLE NUCLEIC ACID COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
SG185544A1 (en) * 2010-05-14 2012-12-28 Fluidigm Corp Nucleic acid isolation methods
SG186899A1 (en) * 2010-07-08 2013-02-28 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
US9115167B2 (en) * 2011-03-10 2015-08-25 Biomics Biotechnologies Co., Ltd. Multi-targets interfering RNA molecules and their applications
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
JP6296434B2 (ja) * 2013-01-25 2018-03-20 国立研究開発法人理化学研究所 機能性核酸分子の構築法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2746803T3 (es) 2013-05-15 2020-03-06 Robert Kruse Traducción intracelular de ARN circular
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CN104419704B (zh) * 2013-09-05 2016-09-14 中国科学院上海生命科学研究院 一种内含子来源环形rna分子及其成环关键核酸序列的应用
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
SG10201805087VA (en) 2013-12-27 2018-07-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
CN105063210A (zh) * 2015-08-12 2015-11-18 中国农业科学院北京畜牧兽医研究所 一种环状rna的鉴定方法
CN107557363B (zh) * 2016-06-30 2021-03-12 中国科学院分子细胞科学卓越创新中心 可诱导型siRNA表达载体及其制备和应用
US20200038427A1 (en) 2017-03-31 2020-02-06 Bonac Corporation Cyclic nucleic acid molecule having gene expression control function
CN110603330B (zh) 2017-04-28 2023-09-05 协和麒麟株式会社 寡核苷酸衍生物或其盐
WO2018237372A1 (en) 2017-06-23 2018-12-27 Cornell University RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT
CN119506283A (zh) * 2017-09-15 2025-02-25 联邦科学技术研究组织 Rna分子
JP7208911B2 (ja) * 2017-10-11 2023-01-19 日東電工株式会社 核酸分子発現の調節
MX2020006150A (es) 2017-12-15 2020-11-11 Flagship Pioneering Innovations Vi Llc Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
CN108251424A (zh) * 2017-12-19 2018-07-06 天利康（天津）科技有限公司 一种单链环状rna和dna及其制备方法和应用
EP3778886A4 (en) * 2018-03-30 2022-11-02 Toray Industries, Inc. Method for producing hairpin single-stranded rna molecule
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
KR102901623B1 (ko) 2019-03-01 2025-12-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드 및 이의 미용적 용도
MA55082A (fr) 2019-03-01 2022-01-05 Flagship Pioneering Innovations Vi Llc Compositions, procédés, et kits pour l'administration de polyribonucléotides
CN121081491A (zh) 2019-03-04 2025-12-09 旗舰创业创新第六有限责任公司 环状多核糖核苷酸及其药物组合物
JP7618577B2 (ja) 2019-03-25 2025-01-21 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 修飾環状ポリリボヌクレオチドを含む組成物及びその使用
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状ｒｎａ組成物及び方法
US20220257794A1 (en) 2019-06-14 2022-08-18 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
US12636369B2 (en) 2019-06-19 2026-05-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
AU2020296190A1 (en) 2019-06-19 2022-01-06 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct
MX2022006854A (es) 2019-12-04 2022-11-30 Orna Therapeutics Inc Composiciones y metodos de arn circular.
TW202142689A (zh) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 用於轉譯之組合物及其使用方法
EP4096681A1 (en) 2020-01-29 2022-12-07 Flagship Pioneering Innovations VI, LLC Delivery of compositions comprising circular polyribonucleotides
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
AU2021275223A1 (en) 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc. Coronavirus antigen compositions and their uses
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
IL300947A (en) 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
AU2022234607B2 (en) 2021-03-10 2025-01-23 Rznomics Inc. Self-circularized RNA structure
AU2022332372B2 (en) 2021-08-27 2025-12-04 Peking University Constructs and methods for preparing circular rna
IL312965A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
MX2024006407A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones de inmunogenos del virus varicela-zoster y sus usos.
CN118510896A (zh) 2021-12-17 2024-08-16 旗舰创业创新六公司 用于在变性条件下富集环状rna的方法
EP4453201A1 (en) 2021-12-22 2024-10-30 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
AU2022420620A1 (en) 2021-12-23 2024-07-04 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN115786374B (zh) * 2022-07-06 2023-10-13 广州吉赛生物科技股份有限公司 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法
EP4612296A1 (en) 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
CN116694638A (zh) * 2023-02-20 2023-09-05 天津微环生物医药科技有限责任公司 环状核酸应用-miRNA抑制剂
EP4680750A1 (en) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions comprising polyribonucleotides and uses thereof
EP4680276A1 (en) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
EP4698150A1 (en) 2023-04-19 2026-02-25 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
EP4702148A1 (en) 2023-04-25 2026-03-04 Ginkgo Bioworks, Inc. Novel internal ribosome entry site (ires) and intron sequences
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025179198A1 (en) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Circular polyribonucleotides and unmodified linear rnas with reduced immunogenicity
WO2026148005A1 (en) 2025-01-03 2026-07-09 Sail Biomedicines, Inc. Compositions and methods for purifying polyribonucleotides
WO2026152164A1 (en) 2025-01-13 2026-07-16 Sail Biomedicines, Inc. Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11137260A (ja) 1997-11-06 1999-05-25 Soyaku Gijutsu Kenkyusho:Kk 抗インフルエンザウイルス環状ダンベル型ｒｎａ−ｄｎａキメラ化合物及び抗インフルエンザウイルス剤
US6210931B1 (en) * 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
IL145778A0 (en) * 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
WO2003070197A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20090247606A1 (en) * 2001-08-28 2009-10-01 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
JP2005517427A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＣ型肝炎ウイルス（ＨＣＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
EP1644531A4 (en) * 2003-06-25 2009-03-11 Somagenics Inc TARGET-INDEPENDENT CIRCULARIZATION AND TOPOLOGICAL ASSOCIATION CAPABLE POLYNUCLEOTIDES
JP4517061B2 (ja) * 2003-08-08 2010-08-04 独立行政法人産業技術総合研究所 ダンベル型ｄｎａの効率的な製造方法
WO2006007569A2 (en) * 2004-07-01 2006-01-19 Somagenics, Inc. Methods of preparation of gene-specific oligonucleotide libraries and uses thereof

Also Published As

Publication number Publication date
AU2008250075B2 (en) 2014-06-19
JP5296328B2 (ja) 2013-09-25
TWI468515B (zh) 2015-01-11
RU2523596C2 (ru) 2014-07-20
UA101806C2 (ru) 2013-05-13
SI2143792T1 (sl) 2014-05-30
TW200909577A (en) 2009-03-01
DK2143792T3 (da) 2014-04-07
IL201975A (en) 2013-12-31
AU2008250075A1 (en) 2008-11-20
EP2143792B1 (en) 2014-01-08
BRPI0811440A2 (pt) 2014-10-21
ES2446040T3 (es) 2014-03-06
HRP20140170T1 (hr) 2014-04-25
US20190292538A1 (en) 2019-09-26
CA2685994A1 (en) 2008-11-20
NZ581251A (en) 2011-11-25
AR072034A1 (es) 2010-08-04
CN101679962A (zh) 2010-03-24
RU2009145502A (ru) 2011-06-20
US20180073020A1 (en) 2018-03-15
US20100137407A1 (en) 2010-06-03
WO2008140126A1 (ja) 2008-11-20
EP2143792A1 (en) 2010-01-13
EP2143792A4 (en) 2011-08-24
MY154495A (en) 2015-06-30
CY1115283T1 (el) 2017-01-04
IL201975A0 (en) 2011-08-01
MX2009011101A (es) 2009-12-11
KR101525633B1 (ko) 2015-06-03
KR20100024407A (ko) 2010-03-05
JP2008278784A (ja) 2008-11-20
PT2143792E (pt) 2014-04-03
CO6241167A2 (es) 2011-01-20
HK1135140A1 (en) 2010-05-28

Similar Documents

Publication Publication Date Title
SI2143792T1 (sl) Enoverižna ciklična RNA in postopek za njeno pripravo
HRP20190408T1 (hr) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
EP2431465A4 (en) METHOD FOR SYNTHESIS OF DOUBLE-STRENGTHED DNA ACCORDING TO AN RNA AND METHOD FOR DNA AMPLIFICATION
GB0802912D0 (en) Thin-film transistor, carbon-based layer and method of production thereof
ZA201008450B (en) Sweetener,methods of preparing sweetener and applications thereof
IL211441A (en) Variety of endolysin, methods of manufacture and use thereof
EP2253414A4 (en) METHOD OF FORMING A THROUGH HOLE, AND PRODUCT HAVING A THROUGH HOLE
PL2295563T3 (pl) Beta-amylaza, kodujący ją gen i sposób jej wytwarzania
EP2299452A4 (en) Microstructure, and method for production thereof
EP2363466A4 (en) TANNASE, CODE GENERATING THEREOF AND METHOD FOR THE PRODUCTION THEREOF
EP2251413A4 (en) GAMMA GLUTAMYLCYSTEIN PRODUCING YEAST AND METHOD FOR PRODUCING A YEAST EXTRACT
EP2186891A4 (en) YEAST FOR TRANSFORMATION, PROCESS FOR TRANSFORMATION AND PROCESS FOR PRODUCTION OF SUBSTANCE
EP2364955A4 (en) NITRATE ELIMINATING BIOREACTOR, METHOD FOR FORMING NITRATE ELIMINATING BIOFILM, AND METHOD FOR REMOVING NITRATES
EP2202319A4 (en) NUCLEIC ACID PROBE AND PROCESS FOR PRODUCING POLYMER FOR PROBE
PL386644A1 (pl) Nowy 7-O- - D-4- metoksyglukopiranozyd izoksantohumolu i sposób jego wytwarzania
PL385170A1 (pl) Nowe poli-bis-(1,2-di-karboksylanoalkino)- oksocyrkonu (IV) oraz sposób ich wytwarzania
PL384176A1 (pl) Nowe podstawione N-sulfonyloformamidyny, ich zastosowanie oraz sposób ich otrzymywania
FI20085040A0 (fi) Menetelmä tuottaa yksinauhaista DNA:ta
PL386883A1 (pl) Sposób wytwarzania testololaktonu (17a-oxa-D-homo-androst-4-en-3,17-dionu)
PL386881A1 (pl) Sposób wytwarzania testololaktonu (17a-oxa-D-homo-androst-4-en-3,17-dionu)
PL386882A1 (pl) Sposób wytwarzania testololaktonu (17a-oxa-D-homo-androst-4-en-3,17-dionu)
PL386884A1 (pl) Sposób wytwarzania testololaktonu (17a-oxa-D-homo-androst-4-en-3,17-dionu)
PL385172A1 (pl) Nowy tetra-μ₃ -oksotetra-μ- dikarboksylanotertbutyloacetylo-μ- izopropanolanocyklotetratytan (IV) oraz sposób jego wytwarzania
PL383379A1 (pl) Sposób wytwarzania 2-hydroksynaftochinonu-1,4
PL386941A1 (pl) Gen mod-rsfp, jego sekwencja, jej otrzymywanie i jego zastosowanie jako gen markerowy